Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.09% | 49.94% | 17.37% | 205.50% | 538.74% |
| Gross Profit | -3.09% | -49.94% | -17.37% | -205.50% | -538.74% |
| SG&A Expenses | 12.49% | -16.72% | 0.86% | 18.59% | 217.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.73% | 21.53% | 10.92% | 114.21% | 397.52% |
| Operating Income | -5.73% | -21.53% | -10.92% | -114.21% | -397.52% |
| Income Before Tax | -18.48% | 9.19% | -148.96% | -44.00% | -316.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.71% | 9.19% | -148.96% | -44.00% | -316.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.71% | 9.19% | -148.96% | -44.00% | -316.50% |
| EBIT | -5.73% | -21.53% | -10.92% | -114.21% | -397.52% |
| EBITDA | -5.75% | -21.39% | -10.93% | -114.18% | -397.64% |
| EPS Basic | 18.68% | 15.02% | -148.73% | 0.26% | -54.76% |
| Normalized Basic EPS | 19.37% | 15.04% | -58.46% | 0.41% | -54.35% |
| EPS Diluted | 18.68% | 15.02% | -148.73% | 0.26% | -54.76% |
| Normalized Diluted EPS | 19.37% | 15.04% | -58.46% | 0.41% | -54.35% |
| Average Basic Shares Outstanding | 47.02% | 6.83% | 0.21% | 44.29% | 169.45% |
| Average Diluted Shares Outstanding | 47.02% | 6.83% | 0.21% | 44.29% | 169.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |